Altered metabolism of tacrolimus in hepatic veno-occlusive disease

Transplant International

Volumn 18, Issue 10, 2005, Pages 1215-1217

  Mori, Takehiko ^a   Shimizu, Takayuki ^a   Yamazaki, Rie ^a   Nakazato, Tomonori ^a   Ikeda, Yasuo ^a   Okamoto, Shincihiro ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hematopoietic stem cell transplantation; Hepatic VOD; Tacrolimus

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; FLUDARABINE; METHOTREXATE; RECOMBINANT PLASMINOGEN ACTIVATOR; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER VEIN OBSTRUCTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CORD BLOOD STEM CELL TRANSPLANTATION; ENDOTHELIUM, VASCULAR; FEMALE; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LIVER; LIVER DISEASES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 28444481014     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00204.x     Document Type: Article

References (11)

1. Venkataramanan R, Swanminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 1995; 29: 404.
2. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990; 22: 57.
3. Jain AB, Abu-Elmagd K, Abdallah H, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993; 33: 606.
4. Abu-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52: 71.
5. Winkler M, Ringe B, Melter M, et al. The use of plasma levels for FK506 dosing in liver-grafted patients. Transpl Int 1994; 7: 329.
6. McDonald GB, Hinds MS, Fisher L, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118: 255.
7. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokin 1991; 21: 42.
8. Kawata A, Imai Y, Inada M, et al. Selective reduction of hepatic cytochrome P450 content in patients with intra-hepatic cholestasis. Gastroenterology 1987; 92: 299.
9. Boswell GW, Bekersky I, Fay J, et al, Tacrolimus pharamacokinetics in BMT patients. Bone Marrow Transplant 1998; 21: 23.
10. Bekersky I, Dressler D, Alak A, Boswell GW, Mekki QA. Comparative tacrolimus pharmacokinetics: normal versus mildly hepatically impaired subjects. J Clin Pharmacol 2001; 41: 628.
11. Itagaki F, Hori T, Tomita T, et al. Effect of ascites on tacrolimus disposition in a liver transplant recipient. Ther Drug Monit 2001; 23: 644.